



: Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No Visit ID : RIND.0000013177

Ref Doctor

: RINDOPV5606

Emp/Auth/TPA ID

: Dr.SELF : APT ID 310277 Collected

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 10:40AM

Reported Status

: 26/Dec/2023 01:20PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN



Page 1 of 13







: Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No

: RIND.0000013177

Visit ID Ref Doctor : RINDOPV5606

Emp/Auth/TPA ID

: Dr.SELF : APT ID 310277 Collected

: 26/Dec/2023 10:15AM

Received Reported : 26/Dec/2023 10:40AM : 26/Dec/2023 01:20PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	16.6	g/dL	13-17	Spectrophotometer
PCV	44.60	%	40-50	Electronic pulse & Calculation
RBC COUNT	4.86	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	92	fL	83-101	Calculated
MCH	34.3	pg	27-32	Calculated
MCHC	37.3	g/dL	31.5-34.5	Calculated
R.D.W	13.3	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,200	cells/cu.mm	4000-10000	Electrical Impedanc
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)	, 'C, \		
NEUTROPHILS	60	%	40-80	Electrical Impedanc
LYMPHOCYTES	31	%	20-40	Electrical Impedanc
EOSINOPHILS	04	%	1-6	Electrical Impedanc
MONOCYTES	05	%	2-10	Electrical Impedanc
BASOPHILS	00	%	<1-2	Electrical Impedanc
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3120	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1612	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	208	Cells/cu.mm	20-500	Calculated
MONOCYTES	260	Cells/cu.mm	200-1000	Calculated
PLATELET COUNT	168000	cells/cu.mm	150000-410000	Electrical impedenc
ERYTHROCYTE SEDIMENTATION RATE (ESR)	13	mm at the end of 1 hour	0-15	Modified Westergre

RBCs ARE NORMOCYTIC NORMOCHROMIC. ANISOCYTOSIS+

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 13





Patient Name : Mr.HARISH CHANDRA JOSHI

Age/Gender : 42 Y 6 M 0 D/M
UHID/MR No : RIND.0000013177

Visit ID : RINDOPV5606

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : APT ID 310277 Collected : 26/Dec/2023 10:15AM

Received : 26/Dec/2023 10:40AM Reported : 26/Dec/2023 02:05PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD EDTA					
BLOOD GROUP TYPE	0	Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE	Forward & Reverse Grouping with Slide/Tube Agglutination			



Page 3 of 13







Patient Name Age/Gender

: Mr.HARISH CHANDRA JOSHI

UHID/MR No : RIND.0000013177 Visit ID

: RINDOPV5606

: 42 Y 6 M 0 D/M

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : APT ID 310277 Collected

: 26/Dec/2023 01:53PM

Received

: 26/Dec/2023 03:08PM : 26/Dec/2023 04:11PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, FASTING , NAF PLASMA	81	mg/dL	70-100	GOD - POD	
-------------------------------	----	-------	--------	-----------	--

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

- 1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	95	mg/dL	70-140	GOD - POD	
HOURS, SODIUM FLUORIDE PLASMA (2	77				
HR)					

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 13







Patient Name : Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No : RI

: RIND.0000013177

Visit ID Ref Doctor : RINDOPV5606

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : APT ID 310277 Collected

Reported

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 02:46PM : 26/Dec/2023 07:40PM

Status

: Final Report

Sponsor Name : ARCOFE

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

HBA1C (GLYCATED HEMOGLOBIN), WHOLE BLOOD EDTA				
HBA1C, GLYCATED HEMOGLOBIN	5.2	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	103	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6-7
FAIR TO GOOD CONTROL	7-8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25% B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 13







Patient Name Age/Gender : Mr.HARISH CHANDRA JOSHI

: 42 Y 6 M 0 D/M

UHID/MR No

: RIND.0000013177

Visit ID

: RINDOPV5606

Ref Doctor Emp/Auth/TPA ID

: APT ID 310277

: Dr.SELF

Collected

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 10:39AM

Reported Status

: 26/Dec/2023 01:14PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

LIPID PROFILE, SERUM				
TOTAL CHOLESTEROL	212	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	234	mg/dL	<150	
HDL CHOLESTEROL	30	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	182	mg/dL	<130	Calculated
LDL CHOLESTEROL	135.2	mg/dL	<100	Calculated
VLDL CHOLESTEROL	46.8	mg/dL	<30	Calculated
CHOL / HDL RATIO	7.07		0-4.97	Calculated

Kindly correlate clinically.

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- **6.** VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 13







Patient Name : Mr.HARISH CHANDRA JOSHI

Age/Gender : 42 Y 6 M 0 D/M

UHID/MR No : RIND.0000013177 Visit ID : RINDOPV5606

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : APT ID 310277 Collected : 26/Dec/2023 10:15AM

Received : 26/Dec/2023 10:39AM Reported : 26/Dec/2023 01:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY				
ARCOFEMI - MEDIWHEEL - FULL E	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324			
Test Name	Result	Unit	Bio. Ref. Range	Method

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.60	mg/dL	0.1-1.2	Azobilirubin
BILIRUBIN CONJUGATED (DIRECT)	0.10	mg/dL	0.1-0.4	DIAZO DYE
BILIRUBIN (INDIRECT)	0.50	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	76	U/L	4-44	JSCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	42.0	U/L	8-38	JSCC
ALKALINE PHOSPHATASE	102.00	U/L	32-111	IFCC
PROTEIN, TOTAL	6.80	g/dL	6.7-8.3	BIURET
ALBUMIN	5.50	g/dL	3.8-5.0	BROMOCRESOL GREEN
GLOBULIN	1.30	g/dL	2.0-3.5	Calculated
A/G RATIO	4.23	A-A	0.9-2.0	Calculated

Kindly correlate clinically.

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment:
- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 13







: Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No Visit ID : RIND.0000013177

Ref Doctor

: RINDOPV5606

Emp/Auth/TPA ID

: Dr.SELF : APT ID 310277 Collected

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 10:39AM

Reported

: 26/Dec/2023 01:14PM

Status : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

RENAL PROFILE/KIDNEY FUNCTION T	EST (RFT/KFT) , SERU	M		
CREATININE	0.73	mg/dL	0.6-1.1	ENZYMATIC METHOD
UREA	21.64	mg/dL	19-43	Urease
BLOOD UREA NITROGEN	10.1	mg/dL	9.0-20.0	Urease
URIC ACID	6.40	mg/dL	4.0-7.0	URICASE
CALCIUM	10.20	mg/dL	8.4-10.2	CPC
PHOSPHORUS, INORGANIC	3.50	mg/dL	2.6-4.4	PNP-XOD
SODIUM	138	mmol/L	135-145	Direct ISE
POTASSIUM	4.3	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	94	mmol/L	98-107	Direct ISE









: Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No

: RIND.0000013177

Visit ID

: RINDOPV5606

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: APT ID 310277

Collected

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 10:39AM

Reported Status : 26/Dec/2023 01:14PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BOD	Y ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

GAMMA GLUTAMYL TRANSPEPTIDASE 66.00 U/L 15-73 Glyclyclycine (GGT), SERUM Nitoranalide



Page 9 of 13









Patient Name : Mr.HARISH CHANDRA JOSHI

Test Name

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No Visit ID

: RIND.0000013177

Ref Doctor

: RINDOPV5606

: Dr.SELF Emp/Auth/TPA ID : APT ID 310277 Collected : 26/Dec/2023 10:15AM

Received : 26/Dec/2023 02:46PM

Reported : 26/Dec/2023 03:31PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

	DEPARTMENT OF	IMMUNOLOG	Υ	
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM					
TRI-IODOTHYRONINE (T3, TOTAL)	1.17	ng/mL	0.7-2.04	CLIA	
THYROXINE (T4, TOTAL)	6.96	μg/dL	5.48-14.28	CLIA	
THYROID STIMULATING HORMONE (TSH)	2.260	μIU/mL	0.34-5.60	CLIA	

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 13









: Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No Visit ID

: RIND.0000013177

Ref Doctor

: RINDOPV5606

: Dr.SELF

Emp/Auth/TPA ID

: APT ID 310277

Collected

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 02:46PM

Reported Status

: 26/Dec/2023 03:21PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324
--

Test Name Result Unit Bio. Ref. Range N	ethod
---	-------

TOTAL PROSTATIC SPECIFIC ANTIGEN	0.450	ng/mL	0-4	CLIA	
(tPSA), SERUM					



Page 11 of 13







: Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No Visit ID : RIND.0000013177

Ref Doctor

: RINDOPV5606

Emp/Auth/TPA ID

: Dr.SELF : APT ID 310277 Collected

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 12:08PM : 26/Dec/2023 01:14PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (C	JE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.5		5-7.5	Bromothymol Blue
SP. GRAVITY	1.025		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				·
URINE PROTEIN	NEGATIVE	E 40	NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE	100	NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE	\ %	NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE	NEGATIVE		NITROPRUSSIDE
UROBILINOGEN	NORMAL	14/1	NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE	NEGATIVE		Dipstick
LEUCOCYTE ESTERASE	NEGATIVE	1/5	NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MO	UNT AND MICROSCOPY			
PUS CELLS	3 - 4	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2 - 3	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 13







: Mr.HARISH CHANDRA JOSHI

Age/Gender

: 42 Y 6 M 0 D/M

UHID/MR No Visit ID

: RIND.0000013177

Ref Doctor

: RINDOPV5606

Emp/Auth/TPA ID

: Dr.SELF

: APT ID 310277

Collected

: 26/Dec/2023 10:15AM

Received

: 26/Dec/2023 11:32AM

Reported Status

: 26/Dec/2023 04:11PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT	OF	CLINICAL	PATHOL	OGY

Unit Method **Test Name** Result Bio. Ref. Range

URINE GLUCOSE(POST PRANDIAL)

NEGATIVE

NEGATIVE

Dipstick

URINE GLUCOSE(FASTING)

NEGATIVE

NEGATIVE

Dipstick

*** End Of Report ***

M.B.B.S, D.C.P Consultant Pathologist Dr. Tanish Mandal

M.B.B.S, M.D (Pathology)

Consultant Pathologist

Dr Nidhi Sachdev

M.B.B.S,MD(Pathology)

Consultant Pathologist

Page 13 of 13

